NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver cirrhosis, within different modes of treatment...
Saved in:
Main Authors: | M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2015-12-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/1037 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
by: Juferdy Kurniawan, et al.
Published: (2024-10-01) -
Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
by: Sarah R. Donaldson, et al.
Published: (2025-01-01) -
Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-12-01) -
Modern modes of chronic hepatitis B treatment in daily clinical practice
by: M. V. Mayevskaya, et al.
Published: (2014-11-01) -
Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
by: Zhang Y, et al.
Published: (2025-01-01)